IL6 and systemic sclerosis: In particular, high serum levels of pro-inflammatory cytokine interleukin-6 (IL-6) and important role of IL-6 in the pathogenesis of SSc were demonstrated, that determined the use of IL-6 as a target for biological therapy of SSc (Sambo et al., 1999).